DoD Traumatic Brain Injury and Psychological Health, Clinical Trial Award | W81XWH 21 S TBIPH1

Opportunity Information: Apply for W81XWH 21 S TBIPH1

The FY21 DoD Traumatic Brain Injury and Psychological Health Clinical Trial Award (CTA) is a funding opportunity from the Department of Defense (DoD), administered through the Congressionally Directed Medical Research Programs (CDMRP) and USAMRDC/USAMRAA, focused on rapidly launching human clinical trials that could meaningfully improve care for traumatic brain injury (TBI) and/or psychological health conditions. The program is aimed at trials with clear clinical application, meaning it is intended to move an intervention into real-world use through evidence generation, whether that intervention is a healthcare product, technology, therapy, drug/biologic, medical device, clinical guidance, an emerging approach, or a new use for something already FDA-approved or FDA-cleared. The emphasis is on impact and speed: funded studies are expected to be ready to start quickly and to produce results that can drive next-step development, adoption, or regulatory progress.

A key point is that this mechanism is strictly for clinical trials, not general clinical research. Under the program definition, a clinical trial is a study in which human participants are prospectively assigned to one or more interventions (including placebo or control) to evaluate effects on biomedical or behavioral outcomes. Applications that propose clinical research without a trial (for example, observational patient-oriented studies that do not assign an intervention) do not fit the intent and will not be funded through this award. Likewise, projects where the main goal is clinical care translation research, such as comparative effectiveness research, implementation science, or healthcare services research, are explicitly not allowed under the CTA and are directed instead to the separate Translational Research Award opportunity. Animal studies are also not allowable because the funding must directly support a human clinical trial. In addition, this announcement cannot be used for studies that require an Exception From Informed Consent (EFIC).

The CTA supports a range of trial maturities, from early feasibility work through larger efficacy studies, organized into three research levels. Research Level 1 supports proof-of-principle and exploratory efforts such as pilot studies, phase 0 or small phase 1 trials, and correlative studies tied to an intervention; these awards run up to 3 years with budgets up to $750,000 in total costs. Research Level 2 supports phase 1 and more advanced trials for promising interventions; these awards run up to 4 years with budgets up to $3 million. Research Level 3 supports larger-scale trials designed to demonstrate efficacy in relevant patient populations; these also run up to 4 years with budgets up to $6 million. Applicants are responsible for choosing the appropriate level based on what they are proposing and how mature the intervention and evidence base are.

To encourage team science and help develop the next generation of investigators, the program includes an Early-Career Investigator Partnering Option, but only for Research Level 1. This option is structured around two principal investigators: an Initiating PI who handles most submission administration and a Partnering PI. Either PI may be the early-career investigator. The application needs to make a convincing case that the partnership is essential, that each PI brings distinct and necessary expertise, and that the work is stronger as a joint effort than as two separate projects. If funded, each PI is named on an individual award within the recipient organization.

Because these are interventional trials, the program has strong expectations around readiness, regulatory planning, and operational rigor. Trials are expected to begin within 6 months of the award date, or within 9 months for FDA-regulated studies, reflecting the program goal of rapid implementation. Preliminary data relevant to the proposed trial is required, and the trial must be built on a sound scientific rationale grounded in critical evaluation of the literature. The application should demonstrate access to an appropriate patient population and present a realistic accrual plan, including how standards of care might affect recruitment or eligibility. The program also expects applicants to document access to the intervention materials (drug, device, or other required supplies) for the full study duration, and to address product quality and stability consistent with applicable FDA manufacturing expectations (for example, GMP or Quality System Regulation standards, depending on product type and development stage).

Regulatory status is a major gatekeeping issue for drug and device trials. If the study uses a drug not approved by the FDA for the intended investigational use, an Investigational New Drug (IND) application under 21 CFR 312 may be required, and applicants must provide evidence from the IRB or FDA if an IND is not required. When an IND is required, the program expects that an IND without partial or complete clinical hold status is already in place by the proposal submission deadline, and that the IND matches the specific product and indication being tested. Similarly, device studies may require an Investigational Device Exemption (IDE) under 21 CFR 812; if required, an IDE without hold status must also be in place by the submission deadline, and the IDE must align with the device and indication proposed (not a modified or derivative version). For trials conducted at international sites, the application must include evidence that submissions to the relevant host-country regulatory agencies have been filed by the submission deadline.

From a trial quality standpoint, applications are expected to reflect Good Clinical Practice (GCP) and include clear objectives, well-justified endpoints and outcome measures, and a detailed statistical analysis plan supported by appropriate statistical expertise. A power analysis and sample size justification are expected so reviewers can see that the study can actually answer its primary question. Applicants also need strong operational plans: a data management plan and appropriate database selection, and for FDA-regulated studies a 21 CFR 11-compliant database with suitable data standards. Safety oversight is not optional; the proposal should include a safety management plan describing pharmacovigilance or other safety monitoring as appropriate, plus a clinical monitoring plan showing how protocol adherence and GCP compliance will be ensured. The program also expects dedicated study coordination capacity to manage IRB and regulatory workflows, oversee multi-site coordination, and support participant recruitment and retention.

The award is also designed to push interventions forward beyond the funded trial. Applications must include a Transition Plan describing how the product or intervention will advance after the award, such as progressing to the next trial phase, moving toward regulatory submission, scaling deployment, or pursuing commercialization or broader implementation. When relevant, applicants should describe the planned product label indication and outline a development plan that would support that indication. The announcement additionally emphasizes the importance of institutional support, including (when applicable) a commitment to act as the FDA regulatory sponsor and fulfill sponsor responsibilities under the relevant FDA regulations.

There are also specific federal transparency and reporting obligations tied to human subjects protections. Funded trials must register on ClinicalTrials.gov before starting. In addition, funded trials must post a copy of the IRB-approved informed consent form used for enrollment on a publicly available federal website, consistent with requirements under 32 CFR 219. These requirements reflect broader federal expectations for public accountability in clinical research.

Military relevance is a central evaluation theme. Projects should clearly explain how the work addresses TBI and/or psychological health in ways that matter to Service Members, Veterans, military beneficiaries, and also the broader public. Competitive proposals typically make a strong case for dual-use value, show appropriate use of military or Veteran populations or resources when relevant, and/or include collaboration with DoD or VA investigators, consultants, programs, or laboratories. The program encourages partnerships between military/Veteran institutions and civilian organizations to leverage infrastructure, expertise, and access to unique datasets or patient populations.

Administratively, this is a discretionary opportunity (CFDA 12.420) open to a broad range of applicant organizations, with awards made as either grants or cooperative agreements depending on the anticipated level of government involvement during execution. The overall FY21 funding pool is expected to be about $58.5 million, supporting roughly 28 awards total (approximately 14 at Level 1, 12 at Level 2, and 2 at Level 3), subject to federal funding availability and the quality and merit of applications. The opportunity was posted August 6, 2021, with an original closing date of December 16, 2021, and awards anticipated no later than September 30, 2022. Funding is tied to FY21 appropriations and is expected to remain available for obligation within the government’s allowable time window, with FY21 funds expiring for use on September 30, 2027.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Traumatic Brain Injury and Psychological Health, Clinical Trial Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Aug 06, 2021.
• Applicants must submit their applications by Dec 16, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 28 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 S TBIPH1

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: